Journal
ALZHEIMERS & DEMENTIA
Volume 10, Issue 6, Pages 646-655Publisher
WILEY
DOI: 10.1016/j.jalz.2013.12.014
Keywords
Alzheimer's disease; Mild cognitive impairment; Prognostic modeling; Risk factors; Aged; Human; Magnetic resonance imaging; Neuropsychological tests; Disease progression
Categories
Funding
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica, Inc.
- Biogen Idec, Inc.
- Bristol-Myers Squibb Company
- Eisai, Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche, Ltd.
- Genentech, Inc.
- GE Healthcare
- Innogenetics, N.V.
- IXICO, Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Medpace, Inc.
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Piramal Imaging
- Servier
- Synarc, Inc.
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- Northern California Institute for Research and Education
- NIH [P30 AGO 10129, K01 AG030514]
- S.D. Bechtel, Jr. Foundation
- National Institutes of Health
- Department of Veterans Affairs
- Department of Defense
- NARSAD
- University of California School of Medicine, S.D.
- NIH
- Commonwealth Fund
- Retirement Research Foundation
- American Federation of Aging Research through the Beeson Career Development Award [K23AG040779]
- [K24-AG031155]
Ask authors/readers for more resources
Background: Our objective in this study was to develop a point-based tool to predict conversion from amnestic mild cognitive impairment (MCI) to probable Alzheimer's disease (AD). Methods: Subjects were participants in the first part of the Alzheimer's Disease Neuroimaging Initiative. Cox proportional hazards models were used to identify factors associated with development of AD, and a point score was created from predictors in the final model. Results: The final point score could range from 0 to 9 (mean 4.8) and included: the Functional Assessment Questionnaire (2-3 points); magnetic resonance imaging (MRI) middle temporal cortical thinning (1 point); MRI hippocampal subcortical volume (1 point); Alzheimer's Disease Cognitive Scale cognitive subscale (2-3 points); and the Clock Test (1 point). Prognostic accuracy was good (Harrell's c = 0.78; 95% CI 0.75, 0.81); 3-year conversion rates were 6% (0-3 points), 53% (4-6 points), and 91% (7-9 points). Conclusions: A point-based risk score combining functional dependence, cerebral MRI measures, and neuropsychological test scores provided good accuracy for prediction of conversion from amnestic MCI to AD. (C) 2014 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available